BPFOPHA@EC2608A

Fosun Pharmaceutical Obtained CSRC Approval for Issuing Sci-Tech Innovation Corporate Bonds

Fosun Pharma Granted Approval for Fumaining and Anlotinib Combined Phase II Clinical Trial for KRAS Mutated Lung Cancer

Fosun Pharmaceutical's Subsidiary Obtains Acceptance for Etomidate Hydrochloride Injection Drug Registration Application

Fosun Pharma's Subsidiary Hengruihansheng Granted Approval for Phase I Clinical Trial of HLX15 for Multiple Myeloma Treatment

Shanghai Henlius Licenses Lung Cancer Drug to Eisai for $155 Million

Fosun Pharmaceutical Subsidiary's Cyclophosphamide Injection Drug Registration Application Accepted by NMPA

F Hutchison and Eisai Sign License Agreement for Serplulimab

Fosun Pharma's Fumasilin® New Indication Drug Listing Application Accepted for Priority Review

Fosun Pharma Deputy Chairman Suggests Use of Health Insurance Data for Elderly Disease Innovation Drug R&D

Fosun Pharmaceutical to Hold Extraordinary General Meeting to Deliberate on Spin-off Listing Proposal

Fosun Pharmaceutical Completes RMB 1 Billion Innovative Technology Bond Issuance

Fosun Pharma's Subsidiary Secures Approval for Clinical Trial in Late-Stage Solid Tumor Treatment

Fosun Pharmaceutical's Subsidiary Obtains Approval for Drug Registration Application

Fosun Pharma's Subsidiary Hengenix Obtains NMPA Approval for HLX701 in Advanced Colorectal Cancer Clinical Trial

Fosun Pharma's Subsidiary Suzhou Er Ye Pharmaceuticals Receives Acceptance for Erythromycin Lactobionate for Injection Registration Application

Establishment of Zhonghui Fuhong Private Equity Investment Fund Partnership

Fosun Wanbang Resubmits Registration Application for R 潽瑞替尼 Capsules

Fosun Pharmaceutical's Subsidiary Kicks Off Phase I Clinical Trial for SRT-007 Prostate Cancer Radiopharmaceutical

Fosun Pharma Plans to Acquire Green Valley Pharmaceutical for 1.412 Billion to Integrate Innovative Drug Pipeline

Fosun Pharma Aims to Acquire 75% Equity of Green Valley Pharmaceutical for 1.412 Billion Yuan

CHK OIL

SHANDONG MOLONG

PETRO-KING

MIE HOLDINGS

D&G TECH

YUANHENG GAS

JX ENERGY

KINETIX SYSTEMS

YANCHANG PETRO

HAO WEN HLDGS

00656

Fosun International (HK:0656) has announced a share buyback plan of up to HK$1 billion, following previous repurchases of approximately 258.9 million shares for HK$1.19 billion since 2022. The company believes its current share price does not reflect its long-term potential. The buyback will occur after the release of its 2025 annual results and before the 2026 annual general meeting, with execution dependent on market conditions. The latest analyst rating for Fosun International is a Hold with a price target of HK$4.00.

Tip Ranks

FOSUN INTL

Fosun International Unveils Up to HK$1 Billion Share Buyback Plan

02196

Shanghai Fosun Pharmaceutical (Group) Co. reported strong shareholder turnout at its 2026 extraordinary general meetings, with over 42% of voting share capital represented. Certain directors abstained from voting on a resolution due to conflicts of interest, but no other shareholders opposed the resolutions, indicating broad support. The latest analyst rating for the stock (HK:2196) is a Hold with a price target of HK$22.00. The company operates in the pharmaceutical industry and has a market cap of HK$75.06B.

FOSUN PHARMA

Fosun Pharma Reports Strong Shareholder Turnout at 2026 Extraordinary Meetings

516930

512290

516610

588130

159992

159849

512010

159837

510660

516500

Shanghai Fosun Pharmaceutical receives regulatory approval for bond issuance

marketscreener

Minsheng Royal CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

E Fund CSI 300 Health Care ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC CSI All Share Health Care Devices ETF

SINOPHARM(CNCM LTD)

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

Guotai SSE STAR Brand Name Drug ETF

China Universal 800 Health Care ETF

Shanghai Fosun Pharmaceutical receives regulatory approval for bond issuance

600196

Fosun Pharma Gets Regulatory Nod for 6 Billion Yuan Bond Issue

Fosun Pharma Gets Regulatory Nod for 6 Billion Yuan Bond Issue

159316

520880

159506

Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China

E Fund Hang Seng SCHK Innovative Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China

Fosun Pharmaceutical Amends Drug Licensing Agreements

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Pharma

Fosun Pharmaceutical Amends Drug Licensing Agreements

Shanghai Fosun Pharma says NMPA accepts drug registration application of moxetomidate hydrochloride injection

Shanghai Fosun Pharma says NMPA accepts drug registration application of moxetomidate hydrochloride injection

Fosun Pharma Unit Gets China Acceptance for Anesthesia Drug Application

Fosun Pharma Unit Gets China Acceptance for Anesthesia Drug Application

Fosun Pharma Gets Regulatory Approval for Myeloma Drug Trial

Fosun Pharma Gets Regulatory Approval for Myeloma Drug Trial

Fosun Health Group plans to build its first overseas hospitals in Indonesia, aiming to expand amid China's push for global healthcare growth. CEO Frank Hu announced the initiative at a conference, highlighting Indonesia's large population and healthcare needs. While term sheets with local partners have been signed, formal contracts are pending. Fosun is also exploring local product distribution and manufacturing partnerships. The company, which operates 19 facilities in China, is targeting markets in South Asia, Southeast Asia, and the Middle East due to their economic growth and healthcare demands.

南华早报

Bosera Hang Seng Health Care ETF(QDII)

Fosun Health to build first overseas hospitals in Indonesia amid global push

159805

600576

516190

517770

512980

301025

08627

Fubo announced that it has reached a strategic cooperation with FOSUN WEALTH INTERNATIONAL HOLDING to independently incubate the AI-driven global one-stop wealth technology platform, Xinglu Technology, located in Hong Kong. Both parties will leverage their respective advantages to engage in deep cooperation in the area of overseas tokenization of real-world assets (RWA) related to cultural and creative intellectual property (IP), jointly exploring compliant innovation development paths and promoting the construction of an ecosystem that transforms cultural and creative IP into efficiently circulating digital assets

AASTOCKS

Penghua CSI Media ETF

Sunriver Culture Tourism

ChinaAMC CSI Cultural Entertainment Media ETF

AXA SPDB CSI Hugangshen Game and Culture Media ETF

GF Fund CSI Media ETF

DOOK

ORANGE TOUR

Fubo Partners with Xinglu Technology to Expand Cultural and Creative IP Tokenization of Real-World Assets Overseas

BPFOPHA@EC2608A(24970.HK)

Fosun International Unveils Up to HK$1 Billion Share Buyback Plan

Fosun Pharma Reports Strong Shareholder Turnout at 2026 Extraordinary Meetings

Shanghai Fosun Pharmaceutical receives regulatory approval for bond issuance

Fosun Pharma Gets Regulatory Nod for 6 Billion Yuan Bond Issue

Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China